Palmo-plantar pustulosis (PPP) is a form of pustular psoriasis which occurs on the palms of the hands and soles of the feet. Recent
research has shown that PPP may be caused by an abnormal pathway in the body's
immune system, involving a protein called interleukin-1 (IL-1). The medication
being tested - anakinra - specifically blocks this IL-1 pathway, and this
clinical trial sets out to test if it therefore improves PPP.
well as testing anakinra as a potential new treatment for PPP, this trial
also hopes to collect information from participants that will help to
explain why and how people get PPP.
The APRICOT study is still looking for new
participants to start as soon as possible! APRICOT is currently open at centres
in Bradford, Bristol, Broomfield Hospital (Essex), Cambridge, Cardiff, Derby,
Dudley, Dundee, Exeter, Glasgow, Harlow, Lancaster, Liverpool, London,
Newcastle, Norwich, Nottingham, Poole, and Salford.
participants who have already completed the 8 week treatment period schedule,
as well as the 12 week follow-up visit, can now take part in an optional 8 week
period of anakinra treatment, as an Open Label Extension (OLE) to the trial.
more information on APRICOT, including how to take part in the clinical trial, please visit the